HNB
ALXN

Huntington National Bank’s Alexion Pharmaceuticals ALXN Stock Holding History

Huntington National Bank’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-222
Closed -$40K – 2155
2021
Q2 		$40K Hold
222
– – ﹤0.01% 1023
2021
Q1 		$34K Buy
222
+89
+67% +$13.8K ﹤0.01% 964
2020
Q4 		$21K Buy
133
+59
+80% +$7.58K ﹤0.01% 1120
2020
Q3 		$8K Hold
74
– – ﹤0.01% 1279
2020
Q2 		$8K Sell
74
-873
-92% -$92.7K ﹤0.01% 1261
2020
Q1 		$84K Buy
947
+34
+4% +$3.34K ﹤0.01% 643
2019
Q4 		$98K Buy
913
+340
+59% +$36.4K ﹤0.01% 713
2019
Q3 		$55K Sell
573
-1,091
-66% -$123K ﹤0.01% 817
2019
Q2 		$217K Sell
1,664
-305
-15% -$39.3K ﹤0.01% 494
2019
Q1 		$265K Buy
1,969
+1,827
+1,287% +$227K ﹤0.01% 475
2018
Q4 		$14K Sell
142
-180
-56% -$21.3K ﹤0.01% 1234
2018
Q3 		$45K Buy
322
+24
+8% +$3.01K ﹤0.01% 1005
2018
Q2 		$37K Sell
298
-3
-1% -$351 ﹤0.01% 1057
2018
Q1 		$34K Sell
301
-589
-66% -$70.4K ﹤0.01% 1080
2017
Q4 		$106K Sell
890
-154
-15% -$18.8K ﹤0.01% 753
2017
Q3 		$146K Sell
1,044
-34
-3% -$4.62K ﹤0.01% 657
2017
Q2 		$131K Buy
1,078
+987
+1,085% +$115K ﹤0.01% 670
2017
Q1 		$11K Sell
91
-194
-68% -$25K ﹤0.01% 1163
2016
Q4 		$35K Sell
285
-7
-2% -$857 ﹤0.01% 1000
2016
Q3 		$36K Buy
292
+14
+5% +$1.8K ﹤0.01% 1001
2016
Q2 		$32K Sell
278
-282
-50% -$40K ﹤0.01% 1022
2016
Q1 		$97K Sell
560
-47
-8% -$6.9K ﹤0.01% 925
2015
Q4 		$115K Buy
607
+25
+4% +$4.37K ﹤0.01% 776
2015
Q3 		$91K Sell
582
-3
-0.5% -$547 ﹤0.01% 891
2015
Q2 		$105K Buy
585
+25
+4% +$4.31K ﹤0.01% 900
2015
Q1 		$97K Buy
560
+39
+7% +$7.06K ﹤0.01% 927
2014
Q4 		$96K Sell
521
-781
-60% -$145K ﹤0.01% 935
2014
Q3 		$216K Sell
1,302
-182
-12% -$29.9K ﹤0.01% 932
2014
Q2 		$232K Sell
1,484
-1,153
-44% -$182K ﹤0.01% 982
2014
Q1 		$401K Buy
2,637
+2,329
+756% +$370K 0.01% 873
2013
Q4 		$41K Sell
308
-2
-0.6% -$240 ﹤0.01% 1153
2013
Q3 		$36K Sell
310
-30
-9% -$3.29K ﹤0.01% 1162
2013
Q2 		$31K Buy
+340
New +$32.8K ﹤0.01% 1184

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Huntington National Bank's ALXN Position: Q3 2021 in Review

Huntington National Bank sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 222 shares — an estimated $40K sold.

Huntington National Bank first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $401K in Q1 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Huntington National Bank reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Huntington National Bank sold 222 Alexion Pharmaceuticals shares in Q3 2021, an estimated $40K.
  • Huntington National Bank first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Huntington National Bank's Alexion Pharmaceuticals position peaked at $401K in Q1 2014.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Huntington National Bank's 13F filing for Q3 2021, filed 28 Oct 2021.